Cerebrospinal fluid and neuroimaging biomarker abnormalities suggest early neurological injury in a subset of individuals during primary HIV infection. - Wikidata - wikimedia - TriplyDB

Cerebrospinal fluid and neuroimaging biomarker abnormalities suggest early neurological injury in a subset of individuals during primary HIV infection.

Cerebrospinal fluid and neuroimaging biomarker abnormalities suggest early neurological injury in a subset of individuals during primary HIV infection.

http://www.wikidata.org/entity/Q36796560

about

HIV-associated neurocognitive disorder--pathogenesis and prospects for treatment Role of HIV in amyloid metabolism Evolving clinical phenotypes in HIV-associated neurocognitive disorders Impact of antiretroviral therapy (ART) timing on chronic immune activation/inflammation and end-organ damage Clinical Trials in Neurovirology: Successes, Challenges, and Pitfalls Hippocampal Neuronal Loss in Infant Macaques Orally Infected with Virulent Simian Immunodeficiency Virus (SIV).Glutamate metabolism and HIV-associated neurocognitive disorders.Evolving character of chronic central nervous system HIV infection.Cerebral metabolite changes prior to and after antiretroviral therapy in primary HIV infection Progressive increase in central nervous system immune activation in untreated primary HIV-1 infection Cerebrospinal fluid (CSF) neuronal biomarkers across the spectrum of HIV infection: hierarchy of injury and detection.Brain alterations within the first 100 days of HIV infection.JAM-A and ALCAM are therapeutic targets to inhibit diapedesis across the BBB of CD14+CD16+ monocytes in HIV-infected individuals.Monocytes mediate HIV neuropathogenesis: mechanisms that contribute to HIV associated neurocognitive disorders HIV effects on age-associated neurocognitive dysfunction: premature cognitive aging or neurodegenerative disease?Compartmentalization, Viral Evolution, and Viral Latency of HIV in the CNS.Determinants of HIV-induced brain changes in three different periods of the early clinical course: A data mining analysis How can we better identify early HIV infections?Imaging neuroinflammation? A perspective from MR spectroscopy.Neurological Response to cART vs. cART plus Integrase Inhibitor and CCR5 Antagonist Initiated during Acute HIV Central and peripheral markers of neurodegeneration and monocyte activation in HIV-associated neurocognitive disorders.Blood-Brain Barrier Function and Biomarkers of Central Nervous System Injury in Rickettsial Versus Other Neurological Infections in Laos.Soluble CD14 in cerebrospinal fluid is associated with markers of inflammation and axonal damage in untreated HIV-infected patients: a retrospective cross-sectional study.Absence of Cerebrospinal Fluid Signs of Neuronal Injury Before and After Immediate Antiretroviral Therapy in Acute HIV Infection.Plasma Concentration of the Neurofilament Light Protein (NFL) is a Biomarker of CNS Injury in HIV Infection: A Cross-Sectional Study.Neurobehavioral Disturbances During Acute and Early HIV Infection.Neuroinflammation in treated HIV-positive individuals: A TSPO PET study.Cerebral white matter integrity during primary HIV infection HIV gp120 sequence variability associated with HAND in Hispanic Women.Putamen volume and its clinical and neurological correlates in primary HIV infection.Neurometabolite Alterations Associated With Cognitive Performance in Perinatally HIV-Infected Children.The complement system, neuronal injury, and cognitive function in horizontally-acquired HIV-infected youth.European Mitochondrial DNA Haplogroups are Associated with Cerebrospinal Fluid Biomarkers of Inflammation in HIV Infection.HIV-associated neurocognitive disorders: recent advances in pathogenesis, biomarkers, and treatment.HIV and neurocognitive dysfunction.Approach to cerebrospinal fluid (CSF) biomarker discovery and evaluation in HIV infection.An overview of the biological and psychosocial context surrounding neurocognition in HIV.Update on HIV dementia and HIV-associated neurocognitive disorders.HIV associated neurocognitive disorders in the modern antiviral treatment era: prevalence, characteristics, biomarkers, and effects of treatment.Neuropathogenesis of HIV: from initial neuroinvasion to HIV-associated neurocognitive disorder (HAND)

P2860

Q26766448-0B60EE84-6E0D-4449-8F5A-85203EA46D9F Q26824179-038A086F-97A3-4AAE-86FE-2CFD9520CA44 Q26859192-3962F8BA-96E3-45AB-9BEF-2E93FD356408 Q27014077-54499F71-2665-4689-A521-352012F81DC8 Q30250271-ACE816D2-95C6-40A3-8368-DFD15567FB1C Q33607923-CE664932-6BE7-404D-BDFA-2775FA919233 Q33903612-49C67F1D-2C6B-4C42-BD6B-B1815CC175EA Q33995713-9CFB5244-FD12-4868-AFD4-E1EB5A3D1282 Q34466521-259EA5D5-FB7F-4D58-920A-C5A043EA7D31 Q34678105-D9A4E89E-EF6E-48D7-B159-3BBC0546E3C8 Q34776835-794400A5-D059-4C2A-BE79-6645567158EA Q34994446-61ABBDF8-FA68-44FD-A1BE-087726E8FB6D Q35005863-54CDBAF8-09E2-494B-92C0-880906253FC4 Q35154529-AAD0D631-7AFF-40FD-BEFE-071BC3859C27 Q35276630-861BF844-3873-46E6-96CA-BCB4B705AAF8 Q35606068-2B6D2C7A-F93B-4853-9C03-78C6C7516634 Q35790117-B097BB2B-E19E-47DB-988D-1C5839EB12CC Q35814304-E9F76AB4-45BA-4ECC-85C4-973EC0163479 Q35824849-C0223AAB-834E-4ED6-B389-39FA69B5EB39 Q35837184-F8746F16-BD1C-4AB2-B8B3-943DF54D4BD1 Q35878624-0F73BD4A-03AF-4B4F-8A8C-F2926017B4BF Q35933867-8F7C7C90-E03F-4FB5-AFA9-D3313F65B0C7 Q35996619-61931E15-B548-48DD-8447-E83DA6934637 Q36250205-8F0C1FEC-8F44-495B-84C7-7AE626840250 Q36538745-63F5C697-8D9D-4A90-8323-973F2294AC8D Q36725430-67B33503-A2EE-400D-81B6-07869CCA5B3C Q36796466-15637743-7489-4313-A208-DE9942D9E5F0 Q37028677-33BC04C5-DE7C-4F9A-875B-3FE99BF9682E Q37042148-535FAC47-EA4A-426E-BEFB-2E39B4BCD170 Q37047808-3F3B6426-1518-458A-A623-FA4407DC5BE0 Q37205326-6042692F-516E-4E25-A221-A5366C2EDDEE Q37452813-165C4595-8809-4C99-8B18-E39368E51E1E Q37701959-A5025095-53A4-4DA9-A9AA-D82CC7353D94 Q37720509-E9BFAFE4-5810-4F74-A888-4B0946FC1C23 Q38122104-FE11E55A-6C34-42CF-9637-A40F2BD8DE2D Q38128778-9E5FDFCE-99E3-4AED-B38E-B30D34573AC9 Q38203412-670F17C5-CE84-45E7-9DB3-8F237EC872CA Q38220991-87491DD0-0D09-48C3-A5A7-38B920B916E9 Q38223328-FF79140F-4092-44E3-BBD1-FC9848EA160F Q38258410-A08177DD-8FAE-4E8C-ADAC-22354783EA38

P2860

Cerebrospinal fluid and neuroimaging biomarker abnormalities suggest early neurological injury in a subset of individuals during primary HIV infection.

http://www.wikidata.org/entity/Q36796560

description

2013 nî lūn-bûn

@nan

2013年の論文

@ja

2013年論文

@yue

2013年論文

@zh-hant

2013年論文

@zh-hk

2013年論文

@zh-mo

2013年論文

@zh-tw

2013年论文

@wuu

2013年论文

@zh

2013年论文

@zh-cn

name

Cerebrospinal fluid and neuroi ...... during primary HIV infection.

@en

type

label

Cerebrospinal fluid and neuroi ...... during primary HIV infection.

@en

prefLabel

Cerebrospinal fluid and neuroi ...... during primary HIV infection.

@en

P1433

Q36796560-3D47BE47-C894-4728-8E0C-7B9E74F02D0E

P1476

Q36796560-CA7E437A-1A2F-4F29-9AB9-CEA8C80EE6C9

P2093

Q36796560-0D4939F4-C3E8-477B-BCF9-859441D5FB06

Q36796560-1FB2DA99-E447-4051-B6CA-1020D6B7F9E9

Q36796560-2F8103DD-8553-4F89-9A29-7F09FFBB5D91

Q36796560-3B978DEC-623A-4E40-B932-82FE8175AC79

Q36796560-42B9DB55-260C-46A4-946A-9B958B1E8E9F

Q36796560-4458911C-38D3-4A7A-BA8B-DAFC7DA48146

Q36796560-60407038-AA92-43C1-9F2F-A84698877ECF

Q36796560-897244BC-22B2-4047-9FF2-7D4131DEB8C4

Q36796560-935160AA-27CC-4980-A642-33E927D4DADE

Q36796560-94D4F6F7-7F4A-43FD-8F99-AA9428984C55

P2860

Q36796560-002E8AEA-D321-4739-A853-C8E2749B72DC

Q36796560-08D6A078-D1B4-4CF1-AD29-846BAB072F75

Q36796560-153A8483-2492-43CE-B4B6-BD1CD1811F33

Q36796560-17F613F6-D61B-438C-ABC4-68945A072F3B

Q36796560-25490A61-2ED4-4BA2-977F-AAAB53364BCD

Q36796560-25A70109-F7EF-41CC-90AF-C2200AB1CDB5

Q36796560-282C2BE3-2AF6-4279-B875-6B33DD780A7C

Q36796560-289780DC-893F-477D-A5F5-5E5A3FCCFC2D

Q36796560-32D8F2FA-1FBD-4CF0-AD24-EFAE611CE095

Q36796560-37BD4A53-8F3A-4FD6-A0A5-9D17B2F65645

P304

Q36796560-A829C945-6091-4E29-8AA2-0A34ADDB4318

P31

Q36796560-81E253E5-019E-420B-8C6A-13EF938107CF

P356

Q36796560-0E6ECFD7-BB0B-48D8-9DA5-5619DCB45571

P407

Q36796560-16D23A07-0166-4C09-A2D8-B3AADA1C76C2

P433

Q36796560-13C43761-AD60-4F9C-9EA2-C0141BD662EB

P478

Q36796560-4077E151-526D-4604-94E4-AC8065C52BBD

P50

Q36796560-19803F72-128D-4C4E-BF85-C47595D0182F

P577

Q36796560-AE6554C6-F50D-4D9D-BF01-6CE9BCC446B1

P5875

Q36796560-44206304-E4DF-4F76-A85C-BB7B54EB2802

P698

Q36796560-797E0090-000A-4D6E-B89E-B840ACFF3F1E

P921

Q36796560-A35EFF2B-E955-4ACB-B255-D083FA3EEB10

Q36796560-AF5F4041-9685-4849-B6AA-16590993C3B4

Q36796560-DCD50FC3-377E-4F7F-A5A6-256A0C0BBC36

P932

Q36796560-91045448-2E99-4498-B85D-7D48FB74616F

P356

P1433

The Journal of Infectious Diseases

P1476

Cerebrospinal fluid and neuroi ...... during primary HIV infection.

@en

P2093

Andrew C Young

http://www.w3.org/2001/XMLSchema#string

Bruce J Brew

http://www.w3.org/2001/XMLSchema#string

Dieter J Meyerhoff

http://www.w3.org/2001/XMLSchema#string

Dietmar Fuchs

http://www.w3.org/2001/XMLSchema#string

Evelyn Lee

http://www.w3.org/2001/XMLSchema#string

Julia Peterson

http://www.w3.org/2001/XMLSchema#string

Kevin Robertson

http://www.w3.org/2001/XMLSchema#string

Lars Hagberg

http://www.w3.org/2001/XMLSchema#string

Magnus Gisslén

http://www.w3.org/2001/XMLSchema#string

Michael J Peluso

http://www.w3.org/2001/XMLSchema#string

P2860

HIV-associated neurocognitive disorders before and during the era of combination antiretroviral therapy: differences in rates, nature, and predictors

Cerebrospinal fluid signs of neuronal damage after antiretroviral treatment interruption in HIV-1 infection

Cerebrospinal fluid HIV infection and pleocytosis: relation to systemic infection and antiretroviral treatment

Decreased clearance of CNS beta-amyloid in Alzheimer's disease

In vivo proton magnetic resonance spectroscopy reveals region specific metabolic responses to SIV infection in the macaque brain.

Amyloid and tau cerebrospinal fluid biomarkers in HIV infection.

Cerebrospinal fluid and plasma biomarkers in Alzheimer disease.

Lower brain glutamate is associated with cognitive deficits in HIV patients: a new mechanism for HIV-associated neurocognitive disorder

Brain creatine elevation and N-Acetylaspartate reduction indicates neuronal dysfunction in the setting of enhanced glial energy metabolism in a macaque model of neuroAIDS

Central nervous system immune activation characterizes primary human immunodeficiency virus 1 infection even in participants with minimal cerebrospinal fluid viral burden.

P304

1703-1712

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1093/INFDIS/JIT088

http://www.w3.org/2001/XMLSchema#string

P407

P433

11

http://www.w3.org/2001/XMLSchema#string

P478

207

http://www.w3.org/2001/XMLSchema#string

P50

Henrik Zetterberg

P577

2013-03-04T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

235787958

http://www.w3.org/2001/XMLSchema#string

P698

23460748

http://www.w3.org/2001/XMLSchema#string

P921

cerebrospinal fluid

P932

3636785

http://www.w3.org/2001/XMLSchema#string